Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

SGLT-2 inhibitors and their potential in the treatment of diabetes.

Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ.

Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. Review.

2.

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES.

Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Review.

PMID:
25891804
3.

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.

Riser Taylor S, Harris KB.

Pharmacotherapy. 2013 Sep;33(9):984-99. doi: 10.1002/phar.1303. Epub 2013 Jun 6. Review.

PMID:
23744749
4.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.

Vivian EM.

Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014. Review.

5.

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.

Shyangdan DS, Uthman OA, Waugh N.

BMJ Open. 2016 Feb 24;6(2):e009417. doi: 10.1136/bmjopen-2015-009417. Review.

6.

Adverse effects and safety of SGLT-2 inhibitors.

Halimi S, Verg├Ęs B.

Diabetes Metab. 2014 Dec;40(6 Suppl 1):S28-34. doi: 10.1016/S1262-3636(14)72693-X. Review.

PMID:
25554069
7.

SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.

Cuypers J, Mathieu C, Benhalima K.

Acta Clin Belg. 2013 Jul-Aug;68(4):287-93. Review.

PMID:
24455799
8.

SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.

Nathan KT, Ahmed-Sarwar N, Werner P.

Consult Pharm. 2016 May;31(5):251-60. doi: 10.4140/TCP.n.2016.260. Review.

PMID:
27178654
9.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Lajara R.

Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15. Review.

PMID:
25316597
10.

Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.

Rizzo M, Al-Busaidi N, Rizvi AA.

Expert Opin Pharmacother. 2015 Feb;16(3):281-4. doi: 10.1517/14656566.2015.981528. Epub 2014 Dec 16.

PMID:
25516459
11.

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Nauck MA.

Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773. eCollection 2014. Review.

12.

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Monami M, Nardini C, Mannucci E.

Diabetes Obes Metab. 2014 May;16(5):457-66. doi: 10.1111/dom.12244. Epub 2013 Dec 29.

PMID:
24320621
13.

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Neumiller JJ.

Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014. Review.

14.

Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

Davidson JA, Kuritzky L.

Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.

PMID:
25414933
15.

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes.

Mikhail N.

World J Diabetes. 2014 Dec 15;5(6):854-9. doi: 10.4239/wjd.v5.i6.854. Review.

16.

Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?

Imprialos KP, Sarafidis PA, Karagiannis AI.

J Hypertens. 2015 Nov;33(11):2185-97. doi: 10.1097/HJH.0000000000000719. Review.

PMID:
26372321
17.

Sodium-glucoser cotransporter 2 inhibitors: glucose lowering against other hypoglycemic agents.

Avranas K, Imprialos K, Stavropoulos K, Lales G, Manafis A, Skalkou A, Kihm L.

Cardiovasc Hematol Disord Drug Targets. 2018 Feb 6. doi: 10.2174/1871529X18666180206160838. [Epub ahead of print]

PMID:
29412124
18.

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.

Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Review.

19.

Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.

Martens P, Mathieu C, Verbrugge FH.

Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):23. doi: 10.1007/s11936-017-0522-x. Review.

PMID:
28299616
20.

Sodium glucose co-transporter inhibitors - A new class of old drugs.

Malhotra A, Kudyar S, Gupta AK, Kudyar RP, Malhotra P.

Int J Appl Basic Med Res. 2015 Sep-Dec;5(3):161-3. doi: 10.4103/2229-516X.165363.

Supplemental Content

Support Center